Search Within

Jose T Baselga

  1. "Moshe Elkabets"
Formats
  1. Journal Article (5)
  2. Meeting Abstract (3)
Groups
  1. Sloan Kettering Institute Postdocs (6)
  2. GSK Faculty (5)
  3. Sloan Kettering Institute Faculty (4)
  4. Center for Molecular Imaging and Biotechnology (CMIB) (3)
  5. Department of Medicine (3)
  6. Molecular Pharmacology and Chemistry Program Faculty (3)

More Groups

People
  1. Maurizio Scaltriti (8)
  2. Moshe Elkabets (8)
  3. Ana Bosch Campos (3)
  4. Natasha Morse (3)
  5. Pau Castel (3)
  6. Eneda Toska (2)

More People

Years
  1. 2017 (1)
  2. 2016 (1)
  3. 2015 (2)
  4. 2014 (3)
  5. 2013 (1)
Publications
  1. Science Translational Medicine (2)
  2. Cancer Cell (1)
  3. Cancer Research (1)
  4. European Journal of Cancer (1)
  5. Molecular Cancer Therapeutics (1)
  6. Science (1)

More Publications

Publishers
  1. American Association for the Advancement of Science (4)
  2. American Association for Cancer Research (2)
  3. Cell Press (1)
  4. Elsevier Inc. (1)

Results (8)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D
    Journal Article

    Toska, E.; Osmanbeyoglu, H. U.; Castel, P.; Chan, C.; Hendrickson, R. C.; Elkabets, M.; Dickler, M. N.; Scaltriti, M.; Leslie, C. S.; Armstrong, S. A.; more...
    Science (2017)

    Fulltext@MSK | Save
  • P-selectin is a nanotherapeutic delivery target in the tumor microenvironment
    Journal Article

    Shamay, Y.; Elkabets, M.; Li, H.; Shah, J.; Brook, S.; Wang, F.; Adler, K.; Baut, E.; Scaltriti, M.; Jena, P. V.; more...
    Science Translational Medicine (2016)

    Fulltext@MSK | Save
  • Inhibition of PIK3CA with BYL719 can overcome resistance to cetuximab in squamous cell carcinoma of the head and neck (SCCHN)
    Meeting Abstract

    Munster, P.; Elkabets, M.; Gilbert, J.; Razak, A. R. A.; Ahn, M. J.; Yen, C. J.; Lee, S. H.; Wang, H. M.; van Herpen, C.; Lim, W. T.; more...
    Molecular Cancer Therapeutics (2015)

    Fulltext@MSK | Save
  • AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas
    Journal Article

    Elkabets, M.; Pazarentzos, E.; Juric, D.; Sheng, Q.; Pelossof, R. A.; Brook, S.; Benzaken, A. O.; Rodon, J.; Morse, N.; Yan, J. J.; more...
    Cancer Cell (2015)

    Fulltext@MSK | Save
  • Blockade of EGFR and HER3 enhances PI3K/Akt antitumor activity in triple negative breast cancer
    Meeting Abstract

    Scaltriti, M.; Tao, J.; Castel, P.; Radosevic-Robin, N.; Elkabets, M.; Auricchio, N.; Juric, D.; Penault-Llorca, F.; Baselga, J.
    Cancer Research (2014)

    Fulltext@MSK | Save
  • Novel regulation of estrogen receptor transcription by the PI3K pathway
    Meeting Abstract

    Toska, E.; Elkabets, M.; Bosch, A.; Litvin, O.; Scaltriti, M.; Baselga, J.
    European Journal of Cancer (2014)

    Fulltext@MSK | Save
  • Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer
    Journal Article

    Tao, J. J.; Castel, P.; Radosevic-Robin, N.; Elkabets, M.; Auricchio, N.; Aceto, N.; Weitsman, G.; Barber, P.; Vojnovic, B.; Ellis, H.; more...
    Science Signaling (2014)

    Fulltext@MSK | Save
  • MTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer
    Journal Article

    Elkabets, M.; Vora, S.; Juric, D.; Morse, N.; Mino-Kenudson, M.; Muranen, T.; Tao, J.; Bosch Campos, A.; Rodon, J.; Ibrahim, Y. H.; more...
    Science Translational Medicine (2013)

    Fulltext@MSK | Save